Mitochondrial membrane potential and nucleosidic inhibitors of HIV reverse transcriptase: a cytometric approach

被引：11
|
作者：
Ferraresi, R
Troiano, L
Rossi, D
Gualdi, E
Lugli, E
Mussini, C
Cossarizza, A
机构：
[1] Univ Modena & Reggio Emilia, Sch Med, Dept Biomed Sci, Chair Immunol,Sect Gen Pathol, I-41100 Modena, Italy
[2] Univ Hosp, Azienda Policlin, Infect Dis Clin, Modena, Italy
来源：
MITOCHONDRION | 2004年 / 4卷 / 2-3期
关键词：
mitochondria; HAART; flow cytometry;
D O I：
10.1016/j.mito.2004.05.015
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Mitochondrial toxicity is a relevant side effect of anti-HIV antiretroviral therapy. Adequate experimental models and advanced technologies are crucial to investigate properly mitochondrial toxicity. Functional flow cytometry allows a rapid and sensitive evaluation of several parameters on single cells, and is an excellent tool to investigate the impact of antiviral drug on mitochondrial activity. We used such approach to analyze in vitro mitochondrial toxicity induced by stavudine and zidovudine on cell lines of different origin (hemopoietic: A301, U937, CEM, K562; hepatic: HepG2), and found that the cell lines had a different sensitivity to the action of the drugs. (C) 2004 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
引用
收藏
页码：271 / 278
页数：8
相关论文
共 50 条
  • [1] Current situation of nucleosidic reverse transcriptase inhibitors
    Van, PN
    ANNALES DE MEDECINE INTERNE, 2000, 151 (04): : 255 - 259
  • [2] Non-nucleosidic reverse transcriptase inhibitors
    Joly, V
    Yeni, P
    ANNALES DE MEDECINE INTERNE, 2000, 151 (04): : 260 - 267
  • [3] Lipodystrophia under nucleosidic inhibitors of the reverse transcriptase:: three cases
    Mercié, P
    Faure, I
    Viallard, JF
    Leng, B
    Pellegrin, JL
    MEDECINE ET MALADIES INFECTIEUSES, 1999, 29 (10): : 648 - 649
  • [4] Anti-tumor activity of non-nucleosidic reverse transcriptase inhibitors
    Landriscina, Matteo
    Spadafora, Corrado
    Cignarelli, Mauro
    Barone, Carlo
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (07) : 737 - 747
  • [5] HIV nucleoside reverse transcriptase inhibitors
    Amblard, Franck
    Patel, Dharmeshkumar
    Michailidis, Eleftherios
    Coats, Steven J.
    Kasthuri, Mahesh
    Biteau, Nicolas
    Tber, Zahira
    Ehteshami, Maryam
    Schinazi, Raymond F.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 240
  • [6] Modified dinucleoside tetraphosphonates, new potential inhibitors of HIV reverse transcriptase
    Shirokova, EA
    Khandazhinskaya, AL
    Skoblov, YS
    Goryunova, LY
    Beabealashvilli, RS
    Krayevsky, AA
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2001, 20 (4-7): : 1033 - 1036
  • [7] Computational approach to HIV resistance prediction to reverse transcriptase and protease inhibitors
    Tarasova, O.
    Mayorov, I.
    Filimonov, D.
    Poroikov, V.
    FEBS OPEN BIO, 2018, 8 : 447 - 448
  • [8] HIV-1 reverse transcriptase inhibitors
    El Safadi, Yazan
    Vivet-Boudou, Valerie
    Marquet, Roland
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2007, 75 (04) : 723 - 737
  • [9] HIV reverse transcriptase inhibitors of natural origin
    Matthée, G
    Wright, AD
    König, GM
    PLANTA MEDICA, 1999, 65 (06) : 493 - 506
  • [10] Investigational reverse transcriptase inhibitors for the treatment of HIV
    Cory, Theodore J.
    Midde, Narasimha M.
    Rao, P. S. S.
    Kumar, Santosh
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (09) : 1219 - 1228
12345